CVS Health Corp. (NYSE:CVS)

Total revenues from customers exhibited a consistent upward trajectory between 2020 and 2024, increasing from US$ 267,908 million to US$ 370,656 million. While overall growth remained positive throughout the period, the rate of expansion decelerated significantly in the final year of the analysis.

Aggregate Revenue Growth

Total revenue increased by approximately 38.3% over the five-year period. The strongest growth phases occurred between 2021 and 2023, whereas 2024 showed a moderated increase compared to previous annual gains.

Pharmacy Segment Performance

Pharmacy revenues, the largest single contributor to total revenue, grew steadily from US$ 171,289 million in 2020 to a peak of US$ 223,452 million in 2023. However, a downturn was observed in 2024, with revenues contracting to US$ 210,272 million.

Premium Revenue Expansion

Premiums demonstrated the most aggressive and consistent growth pattern, rising from US$ 69,364 million in 2020 to US$ 122,896 million in 2024. This represents an increase of approximately 77%, indicating that premiums have become a primary driver of top-line growth.

Front Store and Other Revenue Streams

Front store revenues peaked in 2022 at US$ 22,780 million and subsequently entered a gradual decline, ending 2024 at US$ 21,522 million. In contrast, the "Other" revenue category experienced substantial growth, increasing from US$ 7,600 million in 2020 to US$ 15,966 million in 2024, more than doubling its initial value.

Revenue Mix Shift

A strategic shift in the revenue composition is evident. The proportion of total revenue derived from the Pharmacy segment declined relative to the total, while the contribution from Premiums and Other revenue streams expanded, suggesting a diversification of the company's income sources.